The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was notable for the positive Phase 3 results of daraxonrasib (RMC-6236) in metastatic pancreatic cancer, marking a historic breakthrough in a challenging area of oncology. For a disease long considered one of the toughest challenges in oncology, this is a truly historic moment.
A Transformative Period for Pancreatic Cancer:
Metastatic pancreatic ductal adenocarcinoma (PDAC) has a very low five-year survival rate of about 3%. Traditionally, treatment has involved multi-agent chemotherapy like FOLFIRINOX. However, the Phase 3 RASolute 302 trial revealed that the oral RAS inhibitor daraxonrasib significantly improved survival rates, nearly doubling them compared to standard chemotherapy, representing a major advancement in the treatment of pancreatic cancer in over ten years.
The ASCO data, published in the New England Journal of Medicine, reveal that daraxonrasib has a median overall survival (OS) of 13.2 months in the intent-to-treat population, significantly better than the 6.7 months achieved with standard chemotherapy, reflecting a 60% reduction in death risk (HR 0.40). At 12 months, 53.3% of daraxonrasib recipients were alive versus 18.7% on chemotherapy. The drug also improved progression-free survival (PFS) from 3.5 months to 7.3 months in RAS G12-mutated patients, lowering the risk of disease progression or death by 55%, with objective response rates nearly tripling (33.2% vs. 11.8%).
Overall, daraxonrasib shows efficacy in a wide range of RAS mutations, including G12D, G12V, and G12R, as well as in patients with RAS wild-type tumors.
Understanding Mechanism that disrupts signalling pathway of tumor growths.
Also, daraxonrasib offers significant impact on pancreatic cancer by targeting KRAS mutations, which are present in over 90% of cases. This tri-complex inhibitor interacts with cyclophilin A and RAS proteins, blocking their oncogenic signaling. Unlike previous drugs that address only specific mutations, daraxonrasib functions as a multi-selective inhibitor for both mutant and wild-type RAS proteins, making it highly effective for tumors with KRAS G12 mutations, found in 85% of cases.
Daraxonrasib is a novel tri-complex inhibitor specifically targeting KRAS mutations, which are responsible for over 90% of pancreatic cancers. By forming a complex with cyclophilin A and the RAS protein, it effectively blocks effector binding and inhibits oncogenic signaling. Unlike previous treatments that focus on specific KRAS mutations, daraxonrasib targets both mutant and wild-type RAS proteins, making it an ideal therapeutic option for the majority of pancreatic cancer cases, where 85% of tumors carry KRAS G12 mutations.
Safety Profile:
Daraxonrasib has demonstrated a manageable safety profile, with common treatment-related adverse events including rash (91%), diarrhea (48%), nausea (43%), vomiting (31%), and stomatitis (31%). Most events were mild to moderate (grade 1 or 2), with no new safety concerns identified in the Phase 3 trial. Its oral dosing (300 mg once daily) offers a significant quality-of-life benefit compared to traditional intravenous chemotherapy.
Regulatory Pathways and Milestone:
The FDA has granted daraxonrasib Breakthrough Therapy designation for previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) with KRAS G12 mutations, facilitating its expedited development and review. It has also received Orphan Drug status and a National Priority Voucher. Recently, the FDA approved an Expanded Access Protocol (EAP) in 48 hours, permitting access to daraxonrasib for patients with previously treated metastatic pancreatic cancer during its investigation.
Revolution Medicines plans to submit a New Drug Application for daraxonrasib, based on landmark data. The drug is under investigation in the Phase 3 RASolute-303 trial for frontline metastatic treatment, both as a monotherapy and with chemotherapy. Preclinical research indicates potential for enhanced efficacy by combining daraxonrasib with agents targeting various signaling pathways, aiming to address resistance and improve treatment durability.
A Message for Patients and Clinicians
For patients and clinicians dealing with metastatic pancreatic cancer, ASCO 2026’s daraxonrasib results signify a crucial breakthrough. This targeted therapy has been shown to significantly double survival rates, enhance quality of life, and provide a tolerable oral alternative to traditional chemotherapy. Experts believe these findings will transform treatment approaches across both academic centers and community oncologists, who primarily care for these patients. With upcoming regulatory submission and an existing expanded access program, daraxonrasib is poised to establish a new global standard of care for previously treated metastatic pancreatic cancer, offering renewed hope to patients worldwide.
How Zenovel assist sponsors and trialist in the cure journey of pancreatic cancer?
At Zenovel, our team comprises PhD holders, scientists, doctors, trialist with extensive experience in GCP, GMP, GLP, and regulatory consultancy, specializing in the implementation of clinical trials from Phase I to Phase IV and post-marketing surveillance (PMS), and regulatory consultancy.
- Good Clinical Practice (GCP): We offer comprehensive clinical development support, focusing on risk-based monitoring for bioequivalence and pharmacokinetic studies, management of complex Phase I–III oncology trials, and sponsor oversight to maintain inspection readiness.
- Good Laboratory Practice: Our bioanalytical services encompass the complete drug development lifecycle, adhering to GLP and GCP standards to provide reliable, high-quality data for global regulatory compliance.
- Regulatory Expertise: Zenovel’s experts assist clients in navigating the varying requirements of US FDA, EMA, MHRA, and other global authorities, ensuring GxP compliance and facilitating regulatory submissions and market approvals.
- Global Reach: Our extensive experience in American, Asian, and European countries equips us to offer local expertise and a global perspective, ensuring robust, compliant trial data accepted by regulators worldwide.
The transformation of pancreatic cancer care is now an evidence-based reality. Collaborating with Zenovel enables efficient and compliant navigation of the clinical development pathway for targeted therapies, fostering improved patient outcomes.
References:
- Metastatic pancreatic cancer: Daraxonrasib doubles survival in second-line therapy. Historic result. #ASCO26
- ASCO 2026: All Eyes Are on Daraxonrasib and a Wave of Novel Targeted Therapies in GI Malignancies
- FDA Green Lights Expanded Access Protocol for Daraxonrasib in Pretreated Metastatic PDAC
- Daraxonrasib Yields Significant Survival Advantages vs Chemotherapy in Metastatic Pancreatic Cancer
- Dr Pant on Landmark Efficacy Data With Daraxonrasib in Previously Treated Metastatic PDAC
- Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
- RAS(ON) Therapies on the Horizon to Address KRAS Resistance: Highlight on a Phase III Clinical Candidate Daraxonrasib (RMC-6236)
- Daraxonrasib Shows Significant OS Benefit in Metastatic Pancreatic Cancer
